STOCK TITAN
  1. Home
  2. News
  3. ICU

SeaStar Medical Holding Corp - ICU STOCK NEWS

Welcome to our dedicated news page for SeaStar Medical Holding (Ticker: ICU), a resource for investors and traders seeking the latest updates and insights on SeaStar Medical Holding.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SeaStar Medical Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SeaStar Medical Holding's position in the market.

News
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update
Rhea-AI Summary
SeaStar Medical Holding (Nasdaq: ICU) reports its 2023 financial results, highlighting the FDA approval for Quelimmune™ to treat pediatric patients with acute kidney injury and sepsis. The company is making progress in its NEUTRALIZE-AKI pivotal clinical trial for adult AKI patients. SeaStar Medical also filed its Form 10-K for 2023, with minimal impact on financials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
SeaStar Medical to Present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference
Rhea-AI Summary
SeaStar Medical Holding (ICU) will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference to discuss their solutions for hyperinflammation on vital organs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
conferences
-
News
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
Rhea-AI Summary
SeaStar Medical Holding (ICU) announces the restatement of financial statements for 2022 and interim periods in 2023 due to accounting treatment changes. The restatement will not materially affect cash position or operations. The company continues its pivotal adult acute kidney injury study and prepares for the commercial launch of Quelimmune™ pediatric therapeutic device.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.88%
Tags
none
News
SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients
Rhea-AI Summary
SeaStar Medical Holding Corporation (ICU) announces updates on its NEUTRALIZE-AKI clinical trial for acute kidney injury patients and FDA approval for Quelimmune pediatric device. The company plans to conduct an interim analysis once 100 subjects reach the 90-day primary endpoint in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11%
Tags
clinical trial
-
News
SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024
Rhea-AI Summary
SeaStar Medical Holding Corporation (ICU) sponsors an Industry Symposium on pediatric AKI at the 29th International Conference on Critical Care Nephrology. The company will showcase Quelimmune™ scientific background and clinical data for pediatric AKI due to sepsis or a septic condition on March 13, 2024. The event aims to address the challenges of AKI and multi-organ failure in children.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11%
Tags
none
-
News
Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure
Rhea-AI Summary
SeaStar Medical Holding Corporation (ICU) announces publication of a manuscript discussing the role of chronic systemic inflammation in heart failure patients and the potential application of the Adult Selective Cytopheretic Device to improve outcomes. The manuscript reviews the positive effect of the device in a first-in-human case report, leading to a Breakthrough Device Designation from the FDA. SeaStar also received FDA approval for the Pediatric SCD for use in children with acute kidney injury.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.88%
Tags
none
News
FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury
Rhea-AI Summary
SeaStar Medical Holding Corporation (Nasdaq: ICU) receives FDA approval for SCD-PED, the first product in the Quelimmune product family, for pediatric use in acute kidney injury cases due to sepsis or septic conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.45%
Tags
none
-
News
SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology
Rhea-AI Summary
SeaStar Medical Holding Corporation (Nasdaq: ICU) has announced the issuance of Canadian Patent No. 2814586, expanding its international patent rights for the Selective Cytopheretic Device (SCD) technology. The new patent covers SCD cartridges for treating activated leukocytes and platelets, as well as their use in processing activated leukocytes and platelets. This development presents a significant opportunity to improve the treatment of dysregulated hyperinflammatory responses and potentially reverse organ injury. CEO Eric Schlorff highlighted the innovative and proven approach of SCD in targeting highly active inflammatory cells to quell hyperinflammatory responses resulting from various conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
none
-
News
SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market
Rhea-AI Summary
SeaStar Medical Holding Corporation (Nasdaq: ICU) has announced a securities purchase agreement with an institutional investor to purchase over 10 million shares of common stock in a registered direct offering, along with the issuance of Series A and Series B warrants. The offering is expected to generate approximately $9.0 million in gross proceeds for the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.54%
Tags
offering
News
SeaStar Medical Appoints David A. Green as Chief Financial Officer
Rhea-AI Summary
SeaStar Medical Holding Corporation (Nasdaq: ICU) appoints healthcare industry veteran David A. Green as Chief Financial Officer, effective January 10, 2024, as the company prepares for its first commercial launch for the Selected Cytopheretic Device Pediatric (SCD-PED).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
management
Stock ICU logo
SeaStar Medical Holding Corp

Nasdaq:ICU

ICU Rankings

#4759 Ranked by Market Cap
#5468 Ranked by Stock Gains
N/A Ranked by Dividends

ICU Stock Data

46.71M
35.55M
17.45%
1.44%
5.51%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Denver